Compare LILAK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LILAK | ARDX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | LILAK | ARDX |
|---|---|---|
| Price | $7.71 | $7.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $8.20 | ★ $12.95 |
| AVG Volume (30 Days) | 944.0K | ★ 6.6M |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,433,000,000.00 | $398,234,000.00 |
| Revenue This Year | $1.37 | $22.65 |
| Revenue Next Year | N/A | $31.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 58.12 |
| 52 Week Low | $4.23 | $3.21 |
| 52 Week High | $9.13 | $8.40 |
| Indicator | LILAK | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 64.74 |
| Support Level | $7.34 | $6.73 |
| Resistance Level | $8.11 | $7.25 |
| Average True Range (ATR) | 0.28 | 0.57 |
| MACD | 0.10 | 0.13 |
| Stochastic Oscillator | 69.81 | 80.31 |
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.